Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic
  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Rocket Lab Announces Second Quarter 2022 Financial Results and Guidance for Third Quarter 2022

  • Record revenue of $55.5 million, representing 36% sequential quarter-on-quarter growth and 392% Year-on-Year quarterly revenue growth
  • Third quarter revenue expected to range between $60 million and $63 million

Rocket Lab USA, Inc. (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today shared the financial results for its fiscal second quarter of 2022, ended June 30, 2022.

“In the second quarter of 2022 our team upheld our track record of relentless execution, delivering three successful launches, more than any other small launch provider for the entire year so far. Electron retains its position as the industry’s reliable small launch vehicle, delivering satellites to orbit for a range commercial constellation operators and NASA in the second quarter, quickly followed by back-to-back national security launches for the National Reconnaissance Office after the second quarter end,” said Rocket Lab founder and CEO, Peter Beck. “We continue to push the boundaries with our launch and spacecraft technology, a strategy that also saw us successfully launch the CAPSTONE mission to the Moon for NASA. The highly complex two-phase mission encompassed a flawless launch on Electron and successful deployment to ballistic lunar transfer orbit by our in-house designed and built Lunar Photon spacecraft, paving the way for future deep space missions to Mars and Venus.”

“We are encouraged by broad-based momentum that continued across our space systems business which comprised 66% of our revenue in the second quarter. Space Systems continues to be a significant growth area, with construction of our satellite constellation production facility in Long Beach substantially complete. This production facility will support the manufacturing of contracted spacecraft builds in backlog for a range of customers including Varda Space Industries, Eta Space, the University of California, Berkeley and seventeen 500 kg spacecraft buses for Globalstar as part of a $143M subcontract awarded to Rocket Lab by MDA in the first quarter of this year.” 

Second Quarter 2022 Business Highlights:

  • Launched three successful Electron missions in the second quarter, more than any other U.S. small launch provider for the entire year so far. The missions included the CAPSTONE mission to the Moon for NASA, as well missions that deployed satellites for four commercial constellation companies; BlackSky, Unseenlabs, E-Space, and Swarm, three of which are repeat Electron launch customers.
  • Successfully launched the CAPSTONE mission to the Moon for NASA - the first mission of NASA’s historic Artemis program to return humans to the Moon. This highly complex two-phase mission encompassed a flawless launch on Electron and successful deployment to ballistic lunar transfer orbit by Rocket Lab’s in-house designed and built Lunar Photon spacecraft. The mission was an impressive display of capability across launch and space systems, paving the way for future deep space missions to Mars and Venus.
  • Signed a multi-launch contract with HawkEye 360 to launch 15 satellites across three Electron missions between late 2022 and 2024. The first of the three missions is scheduled to be Rocket Lab’s inaugural mission from Launch Complex 2 in Virginia in December 2022.
  • Completed the first mid-air capture of an Electron booster with a helicopter, advancing the company’s rocket reusability program.
  • Selected to manufacture Solar Array Panel for NASA’s GLIDE spacecraft, the first mission dedicated to surveying changes in the exosphere, the outermost layer of Earth’s atmosphere.
  • Commenced construction on the Neutron launch vehicle production complex in Virginia.
  • Surpassed 50 missions with the company’s MAX Flight Software, a leading off-the-shelf software platform used by aerospace prime contractors, the U.S. Air Force, U.S. DOD organizations, NASA, and commercial spacecraft developers and operators.

Since June 30, 2022 Rocket Lab also:

  • Launched two successful back-to-back missions for the National Reconnaissance Office in just over three weeks, demonstrating responsive launch for the national security community.
  • Introduced the Company’s Responsive Space Program to enable rapid call-up launch and spacecraft capabilities.
  • Selected to supply solar power for the United States Space Force’s new missile warning satellites

Third Quarter 2022 Guidance

For the third quarter of 2022, Rocket Lab expects:

  • Revenue between $60 million and $63 million
  • Launch Services revenue of approximately $23 million
  • Space Systems revenue of between $37 million to $40 million
  • GAAP Gross Margins between 12% to 15%
  • Non-GAAP Gross Margins between 22% to 25%
  • GAAP Operating Expenses $41 million to $43 million
  • Non-GAAP Operating Expenses $27 million to $29 million
  • Expected Interest expenses (Income), net $2 million expense
  • Adjusted EBITDA loss of $8 million to $12 million
  • Basic Shares Outstanding 471 million

Conference Call Information

Rocket Lab will host a conference call for investors at 1:30 p.m. PT (4:30 p.m. ET) today to discuss these business highlights and financial results for our second quarter, to provide our outlook for the third quarter ending September 30, 2022 and other updates. The live webcast and a replay of the webcast will be available on Rocket Lab’s Investor Relations website: https://investors.rocketlabusa.com/events-and-presentations/events

About Rocket Lab

Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, spacecraft components, satellites and other spacecraft and on-orbit management solutions that make it faster, easier and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle and the Photon satellite platform and is developing the Neutron 13-ton payload class launch vehicle. Since its first orbital launch in January 2018, Rocket Lab’s Electron launch vehicle has become the second most frequently launched U.S. rocket annually and has delivered 149 satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab’s Photon spacecraft platform has been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand, and a second launch site in Virginia, USA which is expected to become operational by the end of 2022. To learn more, visit www.rocketlabusa.com.

Forward Looking Statements

This press release may contain certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, including without limitation Q1 2022 guidance, are forward-looking statements. Words such as, but not limited to, “anticipate,” “aim,” “believe,” “contemplate,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “suggest,” “strategy,” “target,” “will,” “would,” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on Rocket Lab’s current expectations and beliefs concerning future developments and their potential effects. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond Rocket Lab’s control), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including risks related to the global COVID-19 pandemic; risks related to government restrictions and lock-downs in New Zealand and other countries in which we operate that could delay or suspend our operations; delays and disruptions in expansion efforts; our dependence on a limited number of customers; the harsh and unpredictable environment of space in which our products operate which could adversely affect our launch vehicle and spacecraft; increased congestion from the proliferation of low Earth orbit constellations which could materially increase the risk of potential collision with space debris or another spacecraft and limit or impair our launch flexibility and/or access to our own orbital slots; increased competition in our industry due in part to rapid technological development and decreasing costs; technological change in our industry which we may not be able to keep up with or which may render our services uncompetitive; average selling price trends; failure of our launch vehicles, spacecraft and components to operate as intended either due to our error in design in production or through no fault of our own; launch schedule disruptions; supply chain disruptions, product delays or failures; design and engineering flaws; launch failures; natural disasters and epidemics or pandemics; changes in governmental regulations including with respect to trade and export restrictions, or in the status of our regulatory approvals or applications; or other events that force us to cancel or reschedule launches, including customer contractual rescheduling and termination rights; risks that acquisitions may not be completed on the anticipated time frame or at all or do not achieve the anticipated benefits and results; and the other risks detailed from time to time in Rocket Lab’s filings with the Securities and Exchange Commission (the “SEC”), including under the heading “Risk Factors” in Rocket Lab’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on March 24, 2022, and elsewhere (including that the impact of the COVID-19 pandemic may also exacerbate the risks discussed therein). There can be no assurance that the future developments affecting Rocket Lab will be those that we have anticipated. You should read this press release with the understanding that our actual results may be materially different from the plans, intentions and expectations disclosed in the forward looking statements we make. All forward looking statements are qualified in their entirety by this cautionary statement. Except as required by law, Rocket Lab is not undertaking any obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Use of Non-GAAP Financial Measures

We supplement the reporting of our financial information determined under Generally Accepted Accounting Principles in the United States of America (“GAAP”) with certain non-GAAP financial information. The non-GAAP financial information presented excludes certain significant items that may not be indicative of, or are unrelated to, results from our ongoing business operations. We believe that these non-GAAP measures provide investors with additional insight into the company's ongoing business performance. These non-GAAP measures should not be considered in isolation or as a substitute for the related GAAP measures, and other companies may define such measures differently. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. GAAP measures for the historical periods disclosed are included in this presentation. We have not provided a reconciliation for forward-looking non GAAP financial measures because, without unreasonable efforts, we are unable to predict with reasonable certainty the amount and timing of adjustments that are used to calculate these non-GAAP financial measures, particularly related to stock based compensation and its related tax effects. The following definitions are provided:

Adjusted EBITDA

Adjusted EBITDA further excludes items of income or loss that we characterize as unrepresentative of our ongoing operations. Such items are excluded from net income to determine adjusted income. Management believes this measure provides investors meaningful insight into results from ongoing operations.

Other Non-GAAP Financial Measures

Non-GAAP gross profit, research and development, net, selling, general and administrative, operating expenses, operating loss and total other income (expense), net further excludes items of income or loss that we characterize as unrepresentative of our ongoing operations. Such items are excluded from the applicable GAAP financial measure. Management believes these non-GAAP measures provide investors meaningful insight into results from ongoing operations.

Notes to Editor: All dollar amounts in this press release are expressed in U.S. dollars, unless otherwise stated.

 

ROCKET LAB U.S.A., INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021

(unaudited; in thousands, except share and per share data)

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

2022

 

2021

 

2022

 

2021

Revenues

 

$

55,474

 

 

$

11,280

 

 

$

96,177

 

 

$

29,472

 

Cost of revenues

 

 

50,516

 

 

 

8,817

 

 

 

87,484

 

 

 

25,598

 

Gross profit

 

 

4,958

 

 

 

2,463

 

 

 

8,693

 

 

 

3,874

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development, net

 

 

19,165

 

 

 

8,529

 

 

 

32,642

 

 

 

15,607

 

Selling, general and administrative

 

 

18,952

 

 

 

7,068

 

 

 

42,030

 

 

 

13,692

 

Total operating expenses

 

 

38,117

 

 

 

15,597

 

 

 

74,672

 

 

 

29,299

 

Operating loss

 

 

(33,159

)

 

 

(13,134

)

 

 

(65,979

)

 

 

(25,425

)

Other income (expense):

 

 

 

 

 

 

 

 

Interest expense, net

 

 

(2,432

)

 

 

(275

)

 

 

(5,421

)

 

 

(402

)

Loss on foreign exchange

 

 

(3,876

)

 

 

(126

)

 

 

(3,896

)

 

 

(405

)

Change in fair value of liability classified warrants

 

 

 

 

 

(2,448

)

 

 

13,482

 

 

 

(5,478

)

Other income (expense), net

 

 

(23

)

 

 

(242

)

 

 

3

 

 

 

(133

)

Total other income (expense), net

 

 

(6,331

)

 

 

(3,091

)

 

 

4,168

 

 

 

(6,418

)

Loss before income taxes

 

 

(39,490

)

 

 

(16,225

)

 

 

(61,811

)

 

 

(31,843

)

Benefit (provision) for income taxes

 

 

2,073

 

 

 

(440

)

 

 

(2,315

)

 

 

(704

)

Net loss

 

$

(37,417

)

 

$

(16,665

)

 

$

(64,126

)

 

$

(32,547

)

Net loss per share attributable to Rocket Lab USA, Inc.:

 

 

 

 

 

 

 

 

Basic and diluted

 

$

(0.08

)

 

$

(0.21

)

 

$

(0.14

)

 

$

(0.41

)

Weighted-average common shares outstanding:

 

 

 

 

 

 

 

 

Basic and diluted

 

 

464,719,924

 

 

 

78,961,096

 

 

 

460,630,324

 

 

 

78,893,969

 

 

ROCKET LAB U.S.A., INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

AS OF JUNE 30, 2022 AND DECEMBER 31, 2021

(in thousands, except share and per share data)

 

 

 

June 30, 2022

 

 

 

 

(unaudited)

 

December 31, 2021

Assets

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

542,511

 

 

$

690,959

 

Accounts receivable, net

 

 

40,183

 

 

 

13,957

 

Contract assets

 

 

4,393

 

 

 

2,490

 

Inventories

 

 

85,683

 

 

 

47,904

 

Prepaids and other current assets

 

 

33,646

 

 

 

19,454

 

Total current assets

 

 

706,416

 

 

 

774,764

 

Non-current assets:

 

 

 

 

Property, plant and equipment, net

 

 

97,031

 

 

 

65,339

 

Intangible assets, net

 

 

84,503

 

 

 

57,487

 

Goodwill

 

 

58,281

 

 

 

43,308

 

Right-of-use assets - operating leases

 

 

31,365

 

 

 

28,424

 

Right-of-use assets - finance leases

 

 

15,921

 

 

 

 

Restricted cash

 

 

4,118

 

 

 

1,116

 

Deferred income tax assets, net

 

 

4,447

 

 

 

5,859

 

Other non-current assets

 

 

2,670

 

 

 

4,550

 

Total assets

 

$

1,004,752

 

 

$

980,847

 

Liabilities and Stockholders’ Equity

 

 

 

 

Current liabilities:

 

 

 

 

Trade payables

 

$

14,156

 

 

$

3,489

 

Accrued expenses

 

 

11,468

 

 

 

10,977

 

Employee benefits payable

 

 

13,632

 

 

 

8,266

 

Contract liabilities

 

 

90,659

 

 

 

59,749

 

Current installments of long-term borrowings

 

 

2,866

 

 

 

2,827

 

Other current liabilities

 

 

11,320

 

 

 

10,999

 

Total current liabilities

 

 

144,101

 

 

 

96,307

 

Non-current liabilities:

 

 

 

 

Long-term borrowings, excluding current installments

 

 

98,649

 

 

 

97,297

 

Non-current operating lease liabilities

 

 

30,370

 

 

 

28,302

 

Non-current finance lease liabilities

 

 

15,744

 

 

 

 

Deferred tax liabilities

 

 

17

 

 

 

466

 

Public and private warrant liabilities

 

 

 

 

 

58,227

 

Other non-current liabilities

 

 

2,417

 

 

 

1,800

 

Total liabilities

 

 

291,298

 

 

 

282,399

 

COMMITMENTS AND CONTINGENCIES

 

 

 

 

Stockholders’ equity:

 

 

 

 

Common stock, $0.0001 par value; authorized shares: 2,500,000,000; issued and outstanding shares: 468,377,065 and 450,180,479 at June 30, 2022 and December 31, 2021, respectively

 

 

47

 

 

 

45

 

Additional paid-in capital

 

 

1,081,390

 

 

 

1,002,106

 

Accumulated deficit

 

 

(369,137

)

 

 

(305,011

)

Accumulated other comprehensive income

 

 

1,154

 

 

 

1,308

 

Total stockholders’ equity

 

 

713,454

 

 

 

698,448

 

Total liabilities and stockholders’ equity

 

$

1,004,752

 

 

$

980,847

 

 

ROCKET LAB U.S.A., INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2022 AND 2021

(unaudited; in thousands)

 

 

 

Six Months Ended June 30,

 

 

 

2022

 

 

 

2021

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

Net loss

 

$

(64,126

)

 

$

(32,547

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

Depreciation and amortization

 

 

13,737

 

 

 

4,847

 

Stock-based compensation expense

 

 

28,827

 

 

 

2,379

 

Loss on disposal of assets

 

 

25

 

 

 

55

 

Loss on extinguishment of long-term debt

 

 

 

 

 

496

 

Amortization of debt issuance costs and discount

 

 

1,392

 

 

 

149

 

Noncash lease expense

 

 

1,526

 

 

 

997

 

Noncash (income) expense associated with liability-classified warrants

 

 

(13,482

)

 

 

5,478

 

Deferred income taxes

 

 

251

 

 

 

(612

)

Changes in operating assets and liabilities:

 

 

 

 

Accounts receivable

 

 

(12,926

)

 

 

(19,580

)

Contract assets

 

 

(2,286

)

 

 

1,201

 

Inventories

 

 

(16,302

)

 

 

(5,347

)

Prepaids and other current assets

 

 

(8,090

)

 

 

2,796

 

Other non-current assets

 

 

2,089

 

 

 

 

Trade payables

 

 

1,992

 

 

 

(3,384

)

Accrued expenses

 

 

(3,433

)

 

 

2,849

 

Employee benefits payables

 

 

3,925

 

 

 

756

 

Contract liabilities

 

 

4,467

 

 

 

5,006

 

Other current liabilities

 

 

(568

)

 

 

(930

)

Non-current lease liabilities

 

 

(1,640

)

 

 

(1,191

)

Other non-current liabilities

 

 

27

 

 

 

 

Net cash used in operating activities

 

 

(64,595

)

 

 

(36,582

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

Purchases of property, equipment and software

 

 

(19,070

)

 

 

(5,699

)

Cash paid for acquisition, net of acquired cash and restricted cash

 

 

(65,073

)

 

 

 

Net cash used in investing activities

 

 

(84,143

)

 

 

(5,699

)

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

Proceeds from the exercise of stock options and public warrants

 

 

3,142

 

 

 

772

 

Proceeds from Employee Stock Purchase Plan

 

 

2,091

 

 

 

 

Proceeds from sale of employees restricted stock units to cover taxes

 

 

24,002

 

 

 

 

Minimum tax withholding paid on behalf of employees for restricted stock units

 

 

(23,741

)

 

 

 

Tax payment for net settled option shares

 

 

(444

)

 

 

 

Payment of contingent consideration

 

 

(5,500

)

 

 

 

Finance lease principal payments

 

 

(116

)

 

 

 

Proceeds from long-term revolving line of credit

 

 

 

 

 

15,000

 

Proceeds from long-term secured term loan

 

 

 

 

 

98,895

 

Repayments on long-term revolving line of credit

 

 

 

 

 

(15,000

)

Payment of deferred transaction costs associated with planned reverse recapitalization transaction

 

 

 

 

 

(2,298

)

Net cash provided by (used in) financing activities

 

 

(566

)

 

 

97,369

 

Effect of exchange rate changes on cash and cash equivalents

 

 

3,858

 

 

 

20

 

Net increase (decrease) in cash and cash equivalents and restricted cash

 

 

(145,446

)

 

 

55,108

 

Cash and cash equivalents, and restricted cash, beginning of period

 

 

692,075

 

 

 

53,933

 

Cash and cash equivalents, and restricted cash, end of period

 

$

546,629

 

 

$

109,041

 

 

ROCKET LAB U.S.A., INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021

(unaudited; in thousands)

 

The tables provided below reconcile the non-GAAP financial measures adjusted EBITDA, gross profit, research and development, net, selling, general and administrative, operating expenses, operating loss and total other income (expense), net with the most directly comparable GAAP financial measures. See above for additional information on the use of these non-GAAP financial measures.

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

NET LOSS

 

$

(37,417

)

 

$

(16,665

)

 

$

(64,126

)

 

$

(32,547

)

Depreciation

 

 

4,318

 

 

 

1,798

 

 

 

7,511

 

 

 

3,555

 

Amortization

 

 

3,331

 

 

 

652

 

 

 

6,226

 

 

 

1,292

 

Stock-based compensation expense

 

 

16,869

 

 

 

1,289

 

 

 

28,827

 

 

 

2,379

 

Transaction costs

 

 

96

 

 

 

 

 

 

471

 

 

 

 

Loss on extinguishment of debt

 

 

 

 

 

795

 

 

 

 

 

 

795

 

Interest expense, net

 

 

2,432

 

 

 

275

 

 

 

5,421

 

 

 

402

 

Change in fair value of liability classified warrants

 

 

 

 

 

2,448

 

 

 

(13,482

)

 

 

5,478

 

Change in fair value of contingent consideration

 

 

(2,500

)

 

 

 

 

 

 

 

 

 

Performance reserve escrow

 

 

1,895

 

 

 

 

 

 

3,790

 

 

 

 

Amortization of inventory step-up

 

 

616

 

 

 

 

 

 

2,618

 

 

 

 

(Benefit) provision for income taxes

 

 

(2,073

)

 

 

440

 

 

 

2,315

 

 

 

704

 

Loss on foreign exchange

 

 

3,876

 

 

 

126

 

 

 

3,896

 

 

 

405

 

ADJUSTED EBITDA

 

$

(8,557

)

 

$

(8,842

)

 

$

(16,533

)

 

$

(17,537

)

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

GAAP Gross profit

 

$

4,958

 

 

$

2,463

 

 

$

8,693

 

 

$

3,874

 

Stock-based compensation

 

 

5,792

 

 

 

305

 

 

 

9,127

 

 

 

604

 

Amortization of purchased intangibles

 

 

751

 

 

 

57

 

 

 

1,316

 

 

 

112

 

Amortization of inventory step-up

 

 

616

 

 

 

 

 

 

2,618

 

 

 

 

Performance reserve escrow

 

 

114

 

 

 

 

 

 

228

 

 

 

 

Non-GAAP Gross Profit

 

$

12,231

 

 

$

2,825

 

 

$

21,982

 

 

$

4,590

 

Non-GAAP Gross Margin

 

 

22.0

%

 

 

25.0

%

 

 

22.9

%

 

 

15.6

%

 

 

 

 

 

 

 

 

 

GAAP Research and development, net

 

$

19,165

 

 

$

8,529

 

 

$

32,642

 

 

$

15,607

 

Stock-based compensation

 

 

(6,350

)

 

 

(574

)

 

 

(11,376

)

 

 

(966

)

Amortization of purchased intangibles

 

 

(1,692

)

 

 

(376

)

 

 

(3,324

)

 

 

(739

)

Non-GAAP Research and development, net

 

$

11,123

 

 

$

7,579

 

 

$

17,942

 

 

$

13,902

 

 

 

 

 

 

 

 

 

 

GAAP Selling, general and administrative

 

$

18,952

 

 

$

7,068

 

 

$

42,030

 

 

$

13,692

 

Stock-based compensation

 

 

(4,727

)

 

 

(410

)

 

 

(8,324

)

 

 

(809

)

Amortization of purchased intangibles

 

 

(780

)

 

 

(25

)

 

 

(1,378

)

 

 

(48

)

Transaction costs

 

 

(96

)

 

 

 

 

 

(471

)

 

 

 

Performance reserve escrow

 

 

(1,781

)

 

 

 

 

 

(3,562

)

 

 

 

Change in fair value of contingent consideration

 

 

2,500

 

 

 

 

 

 

 

 

 

 

Non-GAAP Selling, general and administrative

 

$

14,068

 

 

$

6,633

 

 

$

28,295

 

 

$

12,835

 

 

 

 

 

 

 

 

 

 

GAAP Operating expenses

 

$

38,117

 

 

$

15,597

 

 

$

74,672

 

 

$

29,299

 

Stock-based compensation

 

 

(11,077

)

 

 

(984

)

 

 

(19,700

)

 

 

(1,775

)

Amortization of purchased intangibles

 

 

(2,472

)

 

 

(401

)

 

 

(4,702

)

 

 

(787

)

Transaction costs

 

 

(96

)

 

 

 

 

 

(471

)

 

 

 

Performance reserve escrow

 

 

(1,781

)

 

 

 

 

 

(3,562

)

 

 

 

Change in fair value of contingent consideration

 

 

2,500

 

 

 

 

 

 

 

 

 

 

Non-GAAP Operating expenses

 

$

25,191

 

 

$

14,212

 

 

$

46,237

 

 

$

26,737

 

 

 

 

 

 

 

 

 

 

GAAP Operating loss

 

$

(33,159

)

 

$

(13,134

)

 

$

(65,979

)

 

$

(25,425

)

Total non-GAAP adjustments

 

 

20,199

 

 

 

1,747

 

 

 

41,724

 

 

 

3,278

 

Non-GAAP Operating loss

 

$

(12,960

)

 

$

(11,387

)

 

$

(24,255

)

 

$

(22,147

)

 

 

 

 

 

 

 

 

 

GAAP Total other income (expense), net

 

$

(6,331

)

 

$

(3,091

)

 

$

4,168

 

 

$

(6,418

)

Change in fair value of liability classified warrants

 

 

 

 

 

2,448

 

 

 

(13,482

)

 

 

5,478

 

Loss on foreign exchange

 

 

3,876

 

 

 

126

 

 

 

3,896

 

 

 

405

 

Non-GAAP Total other income (expense), net

 

$

(2,455

)

 

$

(517

)

 

$

(5,418

)

 

$

(535

)

 

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.